Today: 29 April 2026
Browse Category

NSE:MAHINDRA 13 November 2025 - 11 February 2026

M&M profit jumps, Ashok Leyland misses estimates as India’s Feb 11 Q3 results rush hits midday

M&M profit jumps, Ashok Leyland misses estimates as India’s Feb 11 Q3 results rush hits midday

Mahindra & Mahindra reported a 33% jump in Q3 profit to 39.31 billion rupees, driven by SUV and tractor demand but missing analyst estimates. Ashok Leyland’s profit rose 4.5% to 7.96 billion rupees, below forecasts, as costs climbed. Divi’s Labs posted a slight profit dip to 583 crore rupees despite higher income. All three companies took one-off charges related to India’s new labour codes.
11 February 2026
··
Dalal Street in Turmoil: Sensex Plunges 2,500 Points in a Week – Should You Buy the Dip or Brace for More?

Sensex, Nifty Close Flat on Nov 13, 2025; Bank Nifty Hits Record High, Asian Paints Jumps; Rupee Near 88.66 as CPI Prints Record Low

The Sensex closed nearly flat at 84,478.67 and the Nifty 50 at 25,879.15 on Thursday as investors paused ahead of Bihar election results. The Nifty Bank index hit a record intraday high near 58,616. Asian Paints surged to a 52-week high after strong earnings, while Mahindra & Mahindra and Adani Ports slipped. October CPI fell to 0.25% y/y, and the rupee ended at 88.6650 per US dollar.
13 November 2025
··········

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 3:00 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop